go to medicines.ie homepage
  • Home  |  
  • About  |  
  • Links  |  
  • Help
Font Size
Search for:  
select
select
  • SPCs and PILs
  • SPCs Only
  • PILs Only
  Advanced Search
  • What's
    New
      
  • Browse
    Medicines
      
  • Browse
    Active Ingredients
      
  • Browse
    Companies
      
  • Codes
    of Practice
      
  • Adverse
    Reaction Reporting

Abbott Laboratories Ireland Limited

Abbott Laboratories Ireland Limited
4051 Kingswood Drive, Citywest Business Campus, Dublin 24,
Telephone: +353 1 469 1500
Fax: +353 1 469 1501
Summary of Product Characteristics last updated on medicines.ie: 08/11/2010
SPC Forane 99.9% w/w, inhalation vapour, liquid

When a pharmaceutical company changes an SPC or PIL, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 08/11/2010 and displayed until Current
Reasons for adding or updating:
  • Change to section 6.3 - Shelf life
Date of revision of text on the SPC:   01-Nov-2010
Legal Category:   Product subject to medical prescription which may not be renewed (A)

Free-text change information supplied by the pharmaceutical company

The following in-uses stability statement has been added to section 6.3:

"In-use stability: Use within 3 months from opening when stored in the original pacakage and below 25C"
Updated on 26/06/2009 and displayed until 08/11/2010
Reasons for adding or updating:
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 4.7 - Effects on ability to drive and use machines
Date of revision of text on the SPC:   12-Jun-2009
Legal Category:   Product subject to medical prescription which may not be renewed (A)

Free-text change information supplied by the pharmaceutical company


  • In Section 4.2 (Posology and Method of Administration), the MAC table has been separated to show a clear divide between Paediatric and adult patients.
  • In Section 4.4 (Special Warnings and Special Precautions for Use), the following statements has been added 'regardless of anaesthetics employed, maintenance of normal hemodynamics is important for the avoidance of myocardial ishchemia in patients with coronary heart disease.' Also, to the statement regarding repeat exposure increasing the risk of hepatic injury, the following has been added 'especially if the interval is less than 3 months'. Also, the following statement has been added to this section 'The action of non-depolarising relaxants is markedly potentiated with isoflurane. Isoflurane as well as other general anaesthetics, may cause a slight decrease in intellectual function for two to three days following anaesthesia. As with other anaesthetics, small changes in moods and symptoms may persist for up to 6 days after administration.'
  • In Section 4.5 (Interaction With Other Medicaments and Other Forms of Interaction), The following statement has been added; 'The MAC of isoflurane is decreased by the use of nitrous oxide (see section 4.2)'
  • In Section 4.6 (Pregnancy and Lactation), the following statement has been added; 'It is not known whether isoflurane is excreted in human milk therefore, caution should be exercised when isoflurane is administered to a nursing woman.'
  • In Section 4.7 (Effects on Ability to Drive and Use Machines), The following information has been added; 'The action of non-depolarising relaxants is markedly potentiated with isoflurane. Isoflurane as well as other general anaesthetics, may cause a slight decrease in intellectual function for two to three days following anaesthesia. As with other anaesthetics, small changes in moods and symptoms may persist for up to 6 days after administration. This must be taken into account when patients resume normal daily activities, including driving or operating machinery.'
  • In Section 4.8 (Undesiarble Effects), Whole section has been reformatted to comply with MedDRA system and standardised fequencies. Hypersensitivity and related reactions have been added.
  • In Section 5.1 (Pharmacodynamic properties), The ATC code has been added.
Updated on 05/12/2008 and displayed until 26/06/2009
Reasons for adding or updating:
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 6.3 - Shelf life
  • Change to section 6.4 - Special precautions for storage
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 9 - Date of renewal of authorisation
Date of revision of text on the SPC:   05/2008
Legal Category:   prescription only

Free-text change information supplied by the pharmaceutical company

Section 2 (Qualitative and Quanititative Composition) - 'w/w' has been added for clarity
Section 6.3 (Shelf Life) Has been reworded for clarity
Section 6.4 (Special precautions for storage) 'In oder to protect from light' hass been added.
Section 6.6 (Instructions for use/handling) 'Any unsued product or waste material should be disposed of in accordance with local requirements' has been added.
Section 9 (Date of renewal updated)
Updated on 21/08/2007 and displayed until 05/12/2008
Reasons for adding or updating:
  • Change to section 6.5 - Nature and contents of container
  • Change to section 10 - Date of revision of the text
Date of revision of text on the SPC:   08/2007
Legal Category:   prescription only

Free-text change information supplied by the pharmaceutical company

6.5     Nature and contents of Container

 

100 ml and 250 ml Type III Ph.Eur  amber glass bottles, closed with an aluminium cap with LDPE liner

Not all pack sizes may be marketed.

Updated on 09/01/2007 and displayed until 21/08/2007
Reasons for adding or updating:
  • Correction of spelling/typing errors
Updated on 05/10/2006 and displayed until 09/01/2007
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for use
Date of revision of text on the SPC:   09/2006
Legal Category:   prescription only

Free-text change information supplied by the pharmaceutical company

4.4       Special Warnings and Special Precautions for Use

Use of inhaled anesthetic agents has been associated with rare increases in serum potassium levels that have resulted in cardiac arrhythmias and death in paediatric patients during the postoperative period. Patients with latent as well as overt neuromuscular disease, particularly Duchenne muscular dystrophy, appear to be most vulnerable. Concomitant use of succinylcholine has been associated with most, but not all of these cases. These patients also experienced significant elevations in serum creatine kinase levels and in some cases changes in urine consistant with myoglobinuria. Despite the similarity in presentation to malignant hyperthermia, none of these patients exhibited signs or symptoms of muscle rigidity of hypermetabolic state. Early and aggressive intervention to treat the hyperkalaemia and resistant arrhythmias is recommended, as is subsequent evaluation for latent neuromuscular disease.

Updated on 12/05/2006 and displayed until 05/10/2006
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 10 - Date of revision of the text
Updated on 30/01/2006 and displayed until 12/05/2006
Reasons for adding or updating:
  • Change to section 6.4 - Special precautions for storage
  • Change to section 1 - Name of medicinal product
  • Change to section 3 - Pharmaceutical form
  • Change to section 10 - Date of revision of the text
Updated on 18/08/2003 and displayed until 30/01/2006
Reasons for adding or updating:
  • Change to section 1 - Name of medicinal product
Updated on 18/08/2003 and displayed until 18/08/2003
Reasons for adding or updating:
  • Correction of spelling/typing errors
Updated on 17/06/2003 and displayed until 18/08/2003
Reasons for adding or updating:
  • New SPC for medicines.ie

Document Links

 
  View all medicines
from this company
View Document
Bookmark and Share

Active Ingredients

 
   Isoflurane

Versions

 
08/11/2010 to Current
26/06/2009 to 08/11/2010
05/12/2008 to 26/06/2009
21/08/2007 to 05/12/2008
09/01/2007 to 21/08/2007
05/10/2006 to 09/01/2007
12/05/2006 to 05/10/2006
30/01/2006 to 12/05/2006
18/08/2003 to 30/01/2006
18/08/2003 to 18/08/2003
17/06/2003 to 18/08/2003
  • Terms & Conditions | 
  • Accessibility | 
  • Privacy Statement | 
  • Contact Us

Registered Address: Franklin House, 140 Pembroke Road, Dublin 4, Ireland
Registered Number: 254776
Tel: (353 1) 6603350 Fax: (353 1) 6686672 Email: info@ipha.ie

This website is certified by Health On the Net Foundation. Click to verify.

This site complies with the HONcode standard for trustworthy health information: verify here.

logo